Clinical Trial Update: MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027) [Phase 2]

View source ↗

Summary

Completed Phase 2 clinical trial of MK0557 for cognitive impairment in schizophrenia, including paranoid schizophrenia, sponsored by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paranoid Schizophrenia
• Schizophrenia

Drugs mentioned

• MK0557

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Paranoid Schizophrenia, Schizophrenia | Phase 2 | Status: COMPLETED